Paper Title
Case Study of Ranbaxy: A Journey from Fame to Disgrace

Abstract
This case study is about the negligence of Ranbaxy Laboratories and a simultaneous exegesis of the negligence on the part of Indian pharma regulators. It highlights that Ranbaxy Laboratories was reprimanded by the USFDA for breach based on GMP. However, there is no visible evidence of any warnings for the same by the Indian pharma regulators.The biggest mistake by Ranbaxy was the concealment of facts at the time of acquisition by Daiichi Sankyo and later from the USFDA. This case study also highlights the fact that the rules and processes followed by Indian drug regulators are not as stringent as those followed by the US drug regulators. Keywords - Ranbaxy Laboratories Ltd., USFDA, GMP.